Zealand Pharma will have crucial data ready in few weeks
The company is currently waiting on phase III data for glepaglutide, which could open many doors for the company in the future.
by christian bundgaard, translated by daniel pedersen
Zealand Pharma has concluded a phase III study of drug candidate glepaglutide, and is now waiting on important data to come in before sharing it with the public, reports Danish media Finans.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Zealand Pharma sued over misusing trade secrets
For subscribers
